Cost-effectiveness of FDA variance for blood collection from individuals with hereditary hemochromatosis at a 398-bed hospital-based donor center

.blurhash-client-img { display: none !important; }

Paid access

|Mar 2020

References

Leitman SF, Browning JN, Yau YY, et al. Hemochromatosis subjects as allogeneic blood donors; a prospective study. Transfusion 2003;43:1538–44.10.1046/j.1537-2995.2003.00570.x14617312
Search in Google Scholar Back to article
Newman B. Hemochromatosis blood donor programs: marginal for the red blood cell supply but potentially good for patient care. Transfusion 2004;44:1537–8.10.1111/j.0041-1132.2004.00420_1.x15383032
Search in Google Scholar Back to article
FDA Guidance. Variances for blood collection from individuals with hereditary hemochromatosis (HH). August 2001. Available at: (http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/ Guidances/Blood/ucm076719.htm)
Search in Google Scholar Back to article